Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines
- PMID: 8241346
- DOI: 10.1007/BF01715052
Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines
Abstract
Multidrug resistance is frequently found in patients affected by hematological malignancies and has been related to a poor prognosis of acute leukemia. In the present paper we report results concerning the activity of idarubicin, an anthracycline derivative, on the leukemic P388 and P388 doxorubicin-resistant cell lines. The results clearly show that idarubicin inhibits DNA synthesis in the resistant cell line more actively than doxorubicin.
Similar articles
-
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.Anticancer Res. 1993 Mar-Apr;13(2):357-61. Anticancer Res. 1993. PMID: 8517647
-
Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.Cancer Res. 1990 Feb 15;50(4):1165-9. Cancer Res. 1990. PMID: 2297765
-
Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.Cancer Res. 1987 Jul 15;47(14):3752-6. Cancer Res. 1987. PMID: 3474061
-
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.Anticancer Drugs. 1995 Jun;6(3):432-7. doi: 10.1097/00001813-199506000-00011. Anticancer Drugs. 1995. PMID: 7670142
-
Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.Cancer Treat Rep. 1983 Oct;67(10):895-9. Cancer Treat Rep. 1983. PMID: 6354437 Review.